May 2, 2025· Comment from Association for Accessible Medicines· FDA-2020-D-1530-0043
AAM Nitrosamine comments April 2025
FDANonrulemakingFDA-2020-D-1530
Control of Nitrosamine Impurities in Human Drugs; Guidance for Industry; Availability
RIN
—
Last modified
May 20, 2025
Comment window
—
Association for Accessible Medicines filings
3
Activity
Association for Accessible Medicines filed 3 comments on this docket between Dec 10, 2020 and May 2, 2025. 1 other organizations filed here.
What Association for Accessible Medicines filed (3)
Nov 3, 2022· Comment from Association for Accessible Medicines (AAM)· FDA-2020-D-1530-0027
FDA, Please find attached three documents from AAM that AAM staff and AAM members shared with the FDA during a listening session on October 31, 2022. Scott Kuzner Senior Director, Sciences and Regulatory Affairs Association for Accessible Medicines (AAM)
Dec 10, 2020· Comment from The Association for Accessible Medicines (AAM)· FDA-2020-D-1530-0015
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding FDA-2020-D-1530 "Control of Nitrosamine Impurities in Human Drugs".
Abstract
No abstract recorded.
View on regulations.gov →Co-filers (1)
See everyone who commented →- Association for Accessible MedicinesTHIS ORG3 filings · confidence 97%
- Consumer Healthcare Products Associationtrade assoc.2 filings · confidence 97%